SNPMiner Trials (Home Page)
Report for Clinical Trial NCT01182103
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
Epigenetic Regulation of Brain-Derived Neurotropic Factor (BDNF) in Patients With Major Depression
The investigators will (1) detect the associations between brain-derived neurotrophic factor (BDNF) DNA methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in major depressive disorder (MDD) patients, (2) check the correlation between blood BDNF protein and RNA and BDNF rs6265 gene, and (3) discuss the possible mechanisms of epigenetic regulation of BDNF in Taiwanese major depressive patients.
NCT01182103 Major Depressive Disorder MeSH:Depression Depressive Disorder Depressive Disorder, Major
HPO:Depressivity
Primary Outcomes
Description: averaged percentage of methylation at each CpG site listed
Measure: Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls Time: 2 years
Description: Chromatin immunoprecipitation (ChIP) was used to measure histone modification. The unit of our given machine is relative quantification, and a higher value indicated increased histone modification. The detailed method could be found in:
Huebert DJ, Kamal M, O'Donovan A, Bernstein BE: Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 2006; 40: 365-369.
Measure: Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls Time: 2 years
Secondary Outcomes
Description: Serum BDNF levels were measured. MDD patients received antidepressant treatment, a standard biological management. Nothing novel (such as experimental drugs or management) is introduced in the treatment, so the research design is observational (of standard treatment).
The choice of antidepressant drugs depended on the need of patients in natural treatment procedure. They included selective serotonin reuptake inhibitors (SSRI), eg. fluoxetine or paroxetine.
Measure: BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls Time: 2 years
Time Perspective: Cross-Sectional
Primary Outcomes
Description: averaged percentage of methylation at each CpG site listed
Measure: Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls Time: 2 yearsDescription: Chromatin immunoprecipitation (ChIP) was used to measure histone modification. The unit of our given machine is relative quantification, and a higher value indicated increased histone modification. The detailed method could be found in: Huebert DJ, Kamal M, O'Donovan A, Bernstein BE: Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 2006; 40: 365-369.
Measure: Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls Time: 2 yearsSecondary Outcomes
Description: Serum BDNF levels were measured. MDD patients received antidepressant treatment, a standard biological management. Nothing novel (such as experimental drugs or management) is introduced in the treatment, so the research design is observational (of standard treatment). The choice of antidepressant drugs depended on the need of patients in natural treatment procedure. They included selective serotonin reuptake inhibitors (SSRI), eg. fluoxetine or paroxetine.
Measure: BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls Time: 2 yearsCase Control
There is one SNP
SNPs
1 rs6265
Epigenetic Regulation of BDNF in Major Depression The investigators will (1) detect the associations between brain-derived neurotrophic factor (BDNF) DNA methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in major depressive disorder (MDD) patients, (2) check the correlation between blood BDNF protein and RNA and BDNF rs6265 gene, and (3) discuss the possible mechanisms of epigenetic regulation of BDNF in Taiwanese major depressive patients.